Tofacitinib for the treatment of rheumatoid arthritis

References

• Arnett FC, Edworthy SM, Bloch DA et al. The American rheumatism association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum.31, 315–324 (1988).
   PubMed Web of Science ®Google Scholar
• Firestein G. Evolving concepts of rheumatoid arthritis. Nature423, 356–361 (2003).
   PubMed Web of Science ®Google Scholar
• Steinman L. A brief history of TH17, the first major revision in the Th1/Th2 hypothesis of T cell-mediated tissue damage. Nat. Med.13, 139–145 (2007).
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med.204, 1849–1856 (2007).
   PubMed Web of Science ®Google Scholar
• Sato K, Suematsu A, Okamoto K et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med.203, 2673–2682 (2006).
   PubMed Web of Science ®Google Scholar
• Kirkham BW, Lassere MN, Edmonds JP et al. Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum.54, 1122–1131 (2006).
   PubMed Web of Science ®Google Scholar
• Liepe J, Skapenko A, Lipsky P et al. Regulatory T cells in rheumatoid arthritis. Arthritis Res. Ther.7, 93–99 (2005).
   PubMedGoogle Scholar
• Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-α therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β. J. Exp. Med.204, 33–39 (2007).
   PubMed Web of Science ®Google Scholar
• Koch AE, Distler O. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res. Ther.9(Suppl. 2), S3 (2007).
   PubMed Web of Science ®Google Scholar
• Lee DM, Kiener HP, Agarwal SK et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science315, 1006 (2007).
   PubMed Web of Science ®Google Scholar
• McInnes IB, Liew FY. Cytokine networks: towards new therapies for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol.1, 31 (2005).
   PubMedGoogle Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum.54(1), 26–37 (2006).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum.46, 1443–1450 (2002).
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum.41(9), 1552–1563 (1998).
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum.50(6), 1761–1769 (2004).
   PubMed Web of Science ®Google Scholar
• Darnell JE Jr, Kerr IM, Stark GR. JAK–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 3, 264(5164), 1415–1421 (1994).
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol. Rev.228(1), 273–287 (2009).
   PubMed Web of Science ®Google Scholar
• Leonard WJ, O’Shea JJ. Jacks and STATs: biological implications. Annu. Rev. Immunol.16, 29–322 (1998).
   Google Scholar
• Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by γ(c) family cytokines. Nat. Rev. Immunol.9, 480–490 (2009).
   PubMed Web of Science ®Google Scholar
• Bhan, Dari R, Kuriyan J. JAK–STAT signaling. In: Handbook of Cell Signaling (1st Edition). Bradshaw R, Dennis E (Eds). Academic Press, NY, USA, 343–347 (2003).
   Google Scholar
• Russell SM, Tayebi N, Nakajima H et al. Mutation of JAK3 in a patient with SCID: essential role of JAK3 in lymphoid development. Science270, 797–800 (1995).
   PubMed Web of Science ®Google Scholar
• Nosaka T, van Deursen JM, Tripp RA et al. Defective lymphoid development in mice lacking JAK3. Science270, 800–802 (1995).
   PubMed Web of Science ®Google Scholar
• Changelian PS, Flanagan ME, Ball DJ et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science302, 875–878 (2003).
   PubMed Web of Science ®Google Scholar
• Flanagan ME, Blumenkopf TA, Brissette WH et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem.53(24), 8468–8484 (2010).
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol.26, 127–132 (2008).
   PubMed Web of Science ®Google Scholar
• Meyer DM, Jesson MI, Li X et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J. Inflamm.7, 41 (2010).
   Google Scholar
• Chrencik JE, Patny A, Leung IK et al. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J. Mol. Biol.400, 413–433 (2010).
   PubMed Web of Science ®Google Scholar
• Krishnaswami S, Kudlacz E, Yocum S et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of CP-690,550 a Janus kinase inhibitor. AAPS J.11, 36 (2009) (Abstract).
   Google Scholar
• Chow V, Ni G, LaBadie R et al. Open label study to estimate the effect fluconazole on the pharmacokinetics of a JAK3 antagonist (CP-690, 550) in the healthy adult subjects. Clin. Pharmacol. Ther.83, PI-93 (2008) (Abstract).
   Google Scholar
• Chow V, Wilkinson B, LaBadie R et al. Open label study of the pharmacokinetics of a JAK3 antagonist (CP-690,550) and single doses of a oral methotrexate in rheumatoid arthritis subjects. Clin. Pharmacol. Ther.83, PI-92 (2008) (Abstract).
   Google Scholar
• Chow V, Krishnaswami S, Chan G. Pharmacokinetics of CP-690,550, a janus kinase inhibitor, in subjects with impaired renal function and end-stage renal disease. Clin. Pharmacol. Ther.85, PII-86 (2009) (Abstract).
   Google Scholar
• Milici AJ, Kudlacz EM, Audoly L et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res. Ther.10(1), R14 (2008).
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X et al. Modulation of innate and adptative immune responses by tofacitinib (CP-690,550). J. Immunol.186, 4234–4243 (2011).
   PubMed Web of Science ®Google Scholar
• Borie DC, Larson MJ, Flores MG et al. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation80(12), 1756–1764 (2005).
   PubMed Web of Science ®Google Scholar
• Kudlacz E, Perry B, Sawyer P et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant.4(1), 51–57 (2004).
   PubMed Web of Science ®Google Scholar
• Corry R, Winn H, Russel P. Primarily vascularized allografts of hearts in mice. Transplantation16(4), 343–353 (1973).
   PubMed Web of Science ®Google Scholar
• Babany G, Morris RE, Babany I et al. Evaluation of the in vivo dose-response relationship of immunosuppressive drugs using a mouse heart transplant model: application to cyclosporine. J. Pharmacol. Exp. Ther.244(1), 259–262 (1988).
   PubMedGoogle Scholar
• Borie DC, Hausen B et al. Nonhuman primates to study the effects of immunosuppressive drugs: report of a life- supporting technique of renal allotransplantation in Macaca fascicularis. J. Surg. Res.107, 64–74 (2002).
   PubMedGoogle Scholar
• Borie DC, Changelian PS, Larson MJ et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation79, 791–802 (2005).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patient with active rheumatoid arthritis – results of a double-blind, placebo-controlled Phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum.60(7), 1895–1905 (2009).
   PubMed Web of Science ®Google Scholar
• Coombs JH, Bloom BJ, Breedveld FC et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomized, double-blind, placebo-controlled trial. Ann. Rheum. Dis.69, 413–416 (2010).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Cohen S, Wilkinson BE et al. A Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum.64(4), 970–981 (2012).
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Cutolo M, Genovese MC et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum.64(3), 617–629 (2012).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Suzuki M, Nakamura H et al. Phase 2 study of tofacitinib (CP-690, 550) combined with methotrexate in patients with rheumatoid arthritis and inadequate response to methotrexate. Arthritis Care Res. (Hoboken)63(8), 1150–1158 (2011).
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Kremer J, Cush J et al. Phase 3 study of oral JAK inhibitor tasocitinib (CP-690,550) monotherapy in patients with active rheumatoid arthritis. Presented at: Annual Scientific Meeting of the American College of Rheumatology. Atlanta, GA, USA, 6–11 November 2010 (Abstract 4352).
   Google Scholar
• van der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month Phase 3 study. Arthritis Rheum.63(S1017), 2592 (2011) (Abstract).
   Google Scholar
• Burmester G, Blanco R, Charles-Schoemann C et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors: a 6-month Phase 3 study. Arthritis Rheum.63(S279), 718 (2011) (Abstract).
   Google Scholar
• Connell CA, Riese RJ, Wood SP et al. Tasocitinib (CP-690,550), an orally available selective janus kinase inhibitor, exhibits sustained safety and efficacy in the treatment of rheumatoid arthritis over 24 months. Artrhtis Rheum.62(S473), 1129 (2010) (Abstract).
   Google Scholar
• Connell CA, Riese RJ, Wood SP et al. Tasocitinib (CP-690,550) appears to be effective and tolerated when administered either as long-term monotherapy or on background methotrexate in patients with rheumatoid arthritis. Arthritis Rheum.62(S911), 2171 (2010) (Abstract).
   Google Scholar
• Wollenhaupt J, Silverfield JC, Lee EB et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension studies up to 36 months. Arthritis Rheum.63(Suppl. 10), S152–S153 (2011) (Abstract 407).
   Google Scholar
• Cohen S, Radominski SC, Asavatanabodee P et al. Tofacitinib (CP-690,550), an oral Janus Kinase inhibitor: analysis of infections and all-cause mortality across Phase 3 and long-term extension studies in patients with rheumatoid arthritis. Arthritis Rheum.63(Suppl. 10), S153 (2011) (Abstract 409).
   Google Scholar
• van de Sande MGH, de Hair MJH, van der Leij C et al. Different stages of rheumatoid arthritis: features of the sinovium in the preclinical phase. Ann. Rheum. Dis.70, 772–777 (2011).
   PubMed Web of Science ®Google Scholar
• Machado P, Castrejon I, Katchamart W et al. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis.70, 15–24 (2011).
   PubMed Web of Science ®Google Scholar
• Opar A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat. Rev. Drug Discov.9(4), 257–258 (2010).
   PubMed Web of Science ®Google Scholar
• Shuai K, Liu B. Regulation of JAK–STAT signalling in the immune system. Nat. Rev. Immunol.3(11), 900–911 (2003).
   PubMed Web of Science ®Google Scholar